PubMed Health⌕ Search

Biomedical subjects

A B Shcherbakov

Publications and source records attributed to A B Shcherbakov.

18 recordsLinked to original sources
PubMed1995

[Antiendothelial antibodies in systemic scleroderma and Raynaud's disease].

Using ELISA on fixed endothelial hybridoma (EAhy.926) cells we investigated the occurrence of antiendothelial antibodies (AEA) in the sera from patients with scleroderma systematica (SS) (n = 70) and Raynaud's disease (RD) (n = 19). The mean IgG and IgA-AEA levels were significantly higher in the SS patients than RD patients (p < 0.001) and controls (p < 0.001). We have detected circulating IgG-AEA in 64.2% of patients with SS, 35.2% of SS sera were positive for IgA-AEA. In patients with RD, the frequency of AEA corresponded to that of the random population sample. We have found a high incidence of Raynaud's phenomenon, myositis, telangiectasia and marked digital ischaemia (digital ischemic pulp ulcers, digital scars, osteolysis and autoamputation) among AEA positive patients with SS. AEA-positive patients were characterized by high extent and severity of Raynaud's phenomenon and higher average nailfold capillary microscopy scores. No correlations were found between AEA and different clinical or laboratory parameters, including the type of scleroderma (diffuse and limited), the presence of anti-Scl-7O and anticentromere antibodies and the clinical features of SS (lungs, kidneys and heart involvement, esophageal dysfunction, calcinosis, Sjogren's syndrome). There was no significant correlation between the AEA level and patient age, extent of skin involvement (skin score). Thus, in SS, AEA is associated with a peripheral vasculopathy and represent a useful marker for the diagnosis of endothelial dysfunction.

Adolescent↗
PubMed1993

[The role of sympathetic reactivity in the development of Raynaud's syndrome].

Finger skin blood flow was studied in 131 patients with Raynaud's syndrome using laser Doppler flowmetry. Scleroderma systematica, systemic lupus erythematosus, rheumatoid arthritis, Sjogren's disease, mixed connective tissue lesions, Raynaud's disease were diagnosed in 61, 17, 10, 10, 10 and 13 examinees, respectively. Control consisted of 20 healthy subjects. The response of the blood flow was registered in response to functional tests activating sympathetic nervous system: indirect cooling, emotional stress, deep inhalation, Valsalva's test. Hyper-response to the above sympathetic stimulation was noted in none of the groups studied. In scleroderma systematica the reactivity significantly decreased with longer disease duration. It is clear that the study did not confirm the leading role of sympathetic hyperactivity in Raynaud's syndrome pathogenesis.

Adolescent↗
PubMed1992

[The clinical significance of detecting the inhibition of topoisomerase I by the sera of patients with systemic scleroderma].

Topoisomerase I activity was studied by electrophoresis in agarose gel according to plasmid DNA relaxation. Sera from 62 patients with systemic scleroderma, 35 with Raynaud's syndrome, 8 with focal scleroderma, 15 with systemic lupus erythematosus, 20 with rheumatoid arthritis and 20 healthy subjects were examined. Out of 62 sera from SSD patients, anti-topoisomerase activity was found in 67.8% of cases. The test appeared positive in 79% of patients with diffuse and 63% with limited disease patterns. The mean age and disease standing were similar in the positive and negative groups. An increase of the skin count and more frequent occurrence of trophic disorders in patients with inhibition of the enzyme were recorded. 40% of the patients demonstrated the coincidence of the results with the use of the topoisomerase test and ELISA. In patients with other rheumatic diseases and in the healthy subjects, no inhibition of the enzyme was found.

Animals↗
PubMed1992

[The use of Capoten in systemic scleroderma].

Experience gained with the use of captopril has been summarized in 5 patients with sclerodermic renal crisis (true sclerodermic kidney) as well as the results of the double blind clinical trial of captopril in 16 patients with Raynaud's syndrome. Captopril given for a long time in the dose 75-150 mg to the patients with true sclerodermic kidney turned out effective which showed up by a decline and stabilization of arterial pressure, decrease of the intensity of azotemia and headaches, and stabilization of renal function. No convincing data have been obtained, that may confirm a beneficial effect of captopril on Raynaud's syndrome. The drug was applied in a dose of 37.5 mg for 2 weeks.

Acute Disease↗
PubMed1991

[The total proteolytic and collagenolytic activity in the blood cells of patients with systemic scleroderma].

Collagenolytic (CA) and neutral caseinolytic activity (NCA) was studied in extracts from blood cells (neutrophils, mononuclear cells and platelets) of patients suffering from systemic scleroderma (SSD). 23 persons were examined. Of these, 15 had local skin lesions, 8 diffuse lesions. CA, both specific and per 10(6) cells was found to be dramatically decreased (2-4-fold) in all blood cells, whereas NCA was increased in neutrophils and mononuclear cells; in platelets, it remained within normal. The amount of protein in neutrophils and mononuclear cells was lowered 1.2 and 2-fold respectively. In diffuse skin lesions, the amount of protein in cells was lower than in local lesions. It should be noted that in SSD patients examined, the inflammatory process was unmarked. Therefore, the data on substantial changes in proteolytic activity cannot be related to the inflammatory process. A reverse correlation was established between CA in neutrophils and circulating immune complexes as was a reverse correlation between CA in mononuclear cells and blood antinuclear factor. The data presented indicate that proteinases are an important factor of the pathogenesis in SSD. Apparently, SSD is characterized not only by enhanced synthesis of collagen but also by a dramatic reduction of the activity of enzymes that specifically hydrolyze this group of proteins, which leads to a decrease of collagen catabolism and hence, to the development of fibrosis in tissues.

Adult↗
PubMed1989

[The effect of dimethyl sulfoxide on the thromboelastographic indices and the microcirculation in patients with rheumatic diseases].

Using a blind method for assessing the results, a study was made of the effect of dimethylsulfoxide (DMSO) on fibrin formation and microcirculation in 42 patients with rheumatic diseases (rheumatoid arthritis, systemic scleroderma, Raynaud's syndrome). It has been shown that the therapeutic effect of DMSO in rheumatic diseases is determined to a definite degree by its normalizing action on fibrin formation and microcirculation.

Dimethyl Sulfoxide↗
PubMed1988

[Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].

The results of a short and a prolonged treatment of Raynaud's syndrome with calcium antagonists are presented. The efficacy of Nifedipin, Verapamil and Fendiline was evaluated in a 14 day treatment of 61 patients with Raynaud's syndrome. Nifedipin and Fendiline was evaluated in a 14 day treatment of 61 patients with Raynaud's syndrome. Nifedipine and Fendiline were most efficient but Fendiline led to more untoward reactions. Verapamil was least efficient and exerted a weak vasoactive action. The influence of the hemocirculation indices on all drugs studied was insignificant. 20 patients with systemic sclerodermia were given 30-60 mg Nifedipin daily in the course of one year and the frequency, duration and expression of the attacks of Raynaud's syndrome decreased practically twice. The study allows the recommendation of Nifedipin as the drug of choice for the treatment of Raynaud's syndrome in the systemic connective tissue diseases.

Blood Circulation↗
PubMed1988

[Sjögren's syndrome in systemic scleroderma].

Combined investigation of 43 patients with sclerodermia systematica (SSD) was conducted to detect Sjogren's syndrome (SS) and to study SSD association with SS. Four groups of patients were defined: with marked SS (10), primary SS (12), probable SS (13), and without SS manifestations (8). Comparative characterization has shown that SS is detected slightly more frequently in a chronic course of SSD, combines with manifestations of sclerodactyly, telangiectasia, calcinosis, however esophageal hypomobility, indurative skin changes and contractures which are typical of SSD, occur less frequently than in SSD patients without SS. SSD association with SS is characterized by polyarthralgia, arthritis, marked Raynaud's syndrome, the frequency and rather high RF titers, the detection of anti-Ro and anti-La, and a significant rise of the level of circulating immune complexes determined by SS influence. SS manifestations in SSD are retention pains in the parotid glands, signs of clearness on sialograms, periductal sclerosis in the form of rings in morphological investigation of the parotid glands.

Adult↗
PubMed1987

[Treatment of Raynaud's syndrome with calcium entry blockers].

The authors have presented the results of a 14-day open randomized trial of the efficacy of 3 calcium inlet blocking agents: nifedipine, verapamil and phendilin in 61 patients with Raynaud's syndrome. In the group of patients receiving 30-80 mg of nifedipine (20) there was a significant decrease in the frequency and expression of Raynaud's syndrome attacks, a positive effect of varying degree was noted in 19 patients. The drug raised slightly the skin and muscular blood flow and skin temperature. The use of 120-360 mg of verapamil in 21 patients caused no significant inhibition of Raynaud's syndrome and rise of hemocirculation. Phendilin (150-300 mg) though being comparable with nifedipine in efficacy, often produced side-effects resulting in the drug cancellation (8 out of 20). The efficacy of the calcium inlet blocking agents, especially nifedipine, for therapy of Raynaud's syndrome was emphasized.

Adolescent↗
PubMed1985

[Correction of microcirculatory disorders in rheumatic diseases].

The present article is concerned with the problems of pharmacotherapy of microcirculatory disorders (MD) in rheumatic diseases (RD) and with the complex of methods permitting one to judge the intensity of the pathological process at the microcirculatory level. Based on the study of the problems of the correction of MD in more than 300 patients with RD the vasospastic, ischemic, cutaneotrophic, renal and pulmorenal syndromes as well as the DIC syndrome were recognized which require the correction therapy. Differentiated therapy including heparin, deaggregating agents, rheopolyglucin and peripheral vasodilators should be performed with regard to the degree of blood rheological properties derangement and tendency of alterations in the hemostatic potential. To evaluate the treatment, efficacy, biomicroscopy of the vessels of the eyeball conjunctiva and laboratory standardized methods for hemostasis study are the most available techniques.

Administration, Oral↗
PubMed1985

[Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].

Twenty patients with systemic scleroderma (SSD) and Raynaud's syndrome (RS) received 30-80 mg of corinfar, a blocker of calcium channels, during 14 days. Seventeen patients responded to the treatment. The clinical effect was manifested by a decrease in the rate, duration and intensity of RS attacks. Side effects were recorded in 6 patients, but the drug was discontinued only in 2 patients because of the allergic reactions. During treatment, the patients showed an increase in tissue blood flow parameters. Corinfar may be regarded a drug of choice in the treatment of marked RS in SSD.

Adult↗
PubMedDate not supplied

[The clinical value of determining beta-glucuronidase activity in the cells and blood serum of patients with systemic scleroderma].

The spectrophotometric method was used to determine the activity of beta-glucuronidase (BGU) in the cells (neutrophils, mononuclear cells, thrombocytes) in the blood serum of patients with systemic sclerodermia (SSD). The authors revealed a synchronous change in the activity of BGU in all the cells and in the blood serum, and also a decrease in the activity of the enzyme in the concentration of protein in neutrophils, it being very significant in patients with SSD accompanied by trophic changes. There was a direct relationship between the activity of BGU in the blood serum and the level of C-reactive protein and an inverse one between the activity of BGU and the content of circulating immune complexes in the blood. The level of BGU in the blood serum reflects not only the activity of the inflammatory process but also the markedness of trophic changes in patients with SSD.

Blood Platelets↗
PubMedDate not supplied

[A study of Raynaud's syndrome using dynamic infrared thermography].

The method of infrared thermovision was used to study 22 patients with Raynaud's syndrome: 9 patients with sclerodermia, 8 with the primary Raynaud's syndrome and 5 patients with various rheumatic diseases. Patients with recurrent Raynaud's syndrome exhibited adaptation disorders, anomalous distribution of temperature--warming up began not from the distal regions of the bones, as it happens in the norm and with the primary Raynaud's syndrome, but from the proximal regions. Functional tests for sympathetic activation showed the absence of excess reaction in all the groups under examination. Direct cooling of the hand in patients with recurrent Raynaud's syndrome was accompanied by a considerable delay in restoration of the initial temperature. Sublingual administration of nifedipine did not induce a rise in skin temperature in 6 out of 9 patients with sclerodermia. Marked disorders in microcirculation in patients with recurrent Raynaud's syndrome were observed. The role of injury inflicted to arteriovenous anastomoses in pathogenesis of the mentioned syndrome are discussed.

Adolescent↗